NOVARTIS

The FDA approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor for hormone receptor–positive, HER2-negative stage II and III early breast cancer, based on the NATALEE trial showing improved invasive disease-free survival. The combination achieved a 3-year iDFS rate of 90.4% vs 87.1% with endocrine therapy alone, with benefits sustained over 44.2 months.

The FDA approved ribociclib plus an aromatase inhibitor as adjuvant treatment for HR-positive, HER2-negative early breast cancer at high risk of recurrence, based on NATALEE trial data showing reduced recurrence risk by 28.5%.

Ribociclib (Kisqali) in combination with an aromatase inhibitor received FDA approval for adjuvant treatment of HR+/HER2- stage 2 and 3 EBC at high risk of recurrence, based on the NATALEE trial data showing a 25% reduction in risk of disease recurrence and well-tolerated safety.

FDA expands approval of Kisqali for early-stage HR-positive, HER2-negative breast cancer, reducing recurrence risk by 25% after 3 years and 28.5% after 4 years. Available to broader patient groups than Verzenio, it may cause fewer side effects and offers hope to younger women with rising breast cancer rates.

FDA approves Kisqali (ribociclib) with aromatase inhibitor for HR+/HER2- stage II and III EBC at high risk of recurrence, based on NATALEE trial showing 25% reduced risk of recurrence vs. endocrine therapy alone, with consistent benefit across subgroups.

Eli Lilly’s 177Lu-PNT2002, compared to ARPIs like Xtandi and Zytiga, showed efficacy in mCRPC patients positive for PSMA at ESMO 2024. Despite initial negative OS results, crossover adjustments led to a favorable HR of 0.68, likely influencing FDA approval. 177Lu-PNT2002, with lower dosage and fewer cycles than Pluvicto, may challenge Novartis’s market position.

The Global Gene Therapy Market is valued at USD 2.4 billion in 2024, growing at a CAGR of 19.25% during 2024-2035. Gene therapies aim to treat genetic disorders by introducing healthy genes or inactivating faulty ones. The market has seen significant advancements, with 345 companies involved in developing therapies, and 1,100 active clinical trials in April 2024. By 2034, gene therapies are expected to treat over 65.6 million patients.

MetasTx appoints Jennifer Quigley to its Advisory Board; her experience in diagnostics and precision medicine will aid in advancing the company's mission to improve cancer treatment through innovative therapies.

Google DeepMind, in collaboration with Isomorphic Labs, has predicted over 200 million protein structures using AlphaFold, driving breakthroughs in drug discovery. AlphaFold 3, launched in May 2024, achieved a 50% improvement in protein-molecule interaction prediction, enabling the design of drugs targeting specific proteins. DeepMind CEO Demis Hassabis envisions AI-designed drugs addressing hundreds of diseases, with Isomorphic Labs potentially becoming a multi-billion dollar business.